Who’s missing from breast cancer trials? Men, says the FDA

New York Times

9 September 2019 - Men do get breast cancer, but they account for fewer than 1 percent of patients and often receive inadequate care.

In recent years, health officials have pushed aggressively to include more women in clinical trials of new drugs. Gone is the ban that once excluded women of childbearing age from participating in studies. Even scientists who work with animals are now encouraged to include mice and rats of both sexes.

But when it comes to breast cancer, it is men who get short shrift. They are often excluded from clinical trials of new treatments. When new breast cancer drugs come to market, there is little data to indicate whether they are safe or effective in men. Some new drugs are approved only for women.

Read New York Times article

Michael Wonder

Posted by:

Michael Wonder